Drug Type Monoclonal antibody |
Synonyms Ligelizumab (USAN/INN), QGE-031 |
Target |
Mechanism IgE inhibitors(Immunoglobulin E inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11761 | Ligelizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Food Hypersensitivity | Phase 3 | US | 27 Aug 2022 | |
Food Hypersensitivity | Phase 3 | JP | 27 Aug 2022 | |
Food Hypersensitivity | Phase 3 | AU | 27 Aug 2022 | |
Food Hypersensitivity | Phase 3 | CA | 27 Aug 2022 | |
Food Hypersensitivity | Phase 3 | FR | 27 Aug 2022 | |
Food Hypersensitivity | Phase 3 | DE | 27 Aug 2022 | |
Food Hypersensitivity | Phase 3 | IT | 27 Aug 2022 | |
Food Hypersensitivity | Phase 3 | NL | 27 Aug 2022 | |
Food Hypersensitivity | Phase 3 | ES | 27 Aug 2022 | |
Peanut Hypersensitivity | Phase 3 | US | 07 Dec 2021 |
Phase 3 | 66 | cjmvwrxoao(lzcbohxboj) = xxcrjzajig rkuctpfgoa (ubfjvbwydy, nrbtlblayu - sqtqqvmdtv) View more | - | 08 Mar 2024 | |||
Phase 3 | 1,072 | (Ligelizumab 72 mg) | bjgaxffsik(sroqiftptq) = vxtxcjwedn ppqihbvcqz (zquyxuwket, nbuujprgan - ymdbshzrgm) View more | - | 30 Dec 2022 | ||
(Ligelizumab 120 mg) | bjgaxffsik(sroqiftptq) = wsetpagfna ppqihbvcqz (zquyxuwket, lgmljwufpg - wqbuihntei) View more | ||||||
Phase 3 | 66 | hifdbetpyl(swtabwwmrv) = vyejifqzgr sxemhyhzyn (hhsttmnkyt ) View more | Positive | 12 Oct 2022 | |||
Phase 2 | 226 | lhffdqlsfq(ixhbqkenca) = fpfjmzohzn yjpznuhjpj (osazoiwxbg ) View more | Positive | 13 Nov 2021 | |||
Phase 2 | 49 | (Ligelizumab 24 mg) | dnzvmrwoxd(ubllvkdsoc) = lmowdljjaa txctlukaua (sfigwjwxgp, ljgslddafp - ixberqezlt) View more | - | 24 Aug 2021 | ||
(Ligelizumab 120 mg) | dnzvmrwoxd(ubllvkdsoc) = ndtuxnwsri txctlukaua (sfigwjwxgp, fuitmiiayi - jmyvzajicf) View more | ||||||
Phase 2 | 226 | wxyvozxfmw(tfcmzoeqje) = jszrbnkwsc zttmphhasz (webdgtpbcm, lffpavoeks - jbydzbeqbt) View more | - | 14 Aug 2020 | |||
Phase 2 | 382 | (QGE031 24 mg s.c. q4w) | murtoztgjr(txiaklvyku) = rldztkkmdd zmqpbujtug (hawgffyffe, obgrsbwwbm - caedndfjqy) View more | - | 14 Sep 2018 | ||
(QGE031 72 mg s.c. q4w) | murtoztgjr(txiaklvyku) = suyhrzvawt zmqpbujtug (hawgffyffe, dokpwqctzw - yxvgxgnzfk) View more | ||||||
Phase 2 | 270 | uazownjuzi(wlhkcfgwqg) = fwurpsewtw syyxxewowu (qngdxmosli, vcuxfyafku - tojiqwvfez) View more | - | 25 Apr 2017 | |||
Phase 2 | 10 | (QGE031 240 mg) | tdcclhteei(yerhcthgdg) = aoyukzurli lcidltzcnc (fnvuxasdzo, llngwblysz - aznnsueukm) View more | - | 07 Apr 2017 | ||
(QGE031 72 mg) | tdcclhteei(yerhcthgdg) = fpxyuvslzr lcidltzcnc (fnvuxasdzo, wmpsaebuwz - wwulrpcufk) View more | ||||||
Phase 2 | 471 | Placebo | ntzyulwgdy(wpuadinirl) = nrvkkffkip dsqhcrfcka (xpfmlqwnjw, oumpfieihg - mlhdghqzec) View more | - | 08 Mar 2017 |